Request for Proposals: Improving Shared Decision Making in Hemophilia (United States)

Pfizer and the Hemostasis & Thrombosis Research Society (HTRS) are offering an Independent Medical Education (IME) Grant to support Hemophilia Visiting Professorship Programs in the United States. Eligible organizations can receive up to USD 6,000 to host a one- or two-day educational programme focused on hemophilia care, shared decision-making, emerging therapies, and multidisciplinary collaboration, while HTRS separately covers the Visiting Professor’s travel and honorarium.

Pfizer and HTRS Independent Medical Education Grant for Hemophilia Visiting Professorships

What is the Hemophilia Visiting Professorship Grant?

The Pfizer and Hemostasis & Thrombosis Research Society (HTRS) Independent Medical Education Grant supports organizations seeking to strengthen education in hemophilia care through a Visiting Professorship Program.

The initiative enables eligible organizations to host one or two expert HTRS-selected Visiting Professors for educational programmes lasting up to two days. The programme is designed to address identified educational gaps, improve clinical knowledge, promote multidisciplinary collaboration, and enhance patient care through evidence-based medical education.

Approximately nine organizations are expected to receive funding.

Funding Overview

Successful applicants may receive funding to support the local delivery of the educational programme.

Funding Details

Maximum grant amount: Up to USD 6,000
Supports local programme logistics
Approximately nine grants available

Eligible Grant Expenses

Funding may be used for:

Meeting room rental
Audiovisual equipment and technical support
On-site event management
Staffing
Programme planning
Other local logistical expenses

Expenses Covered Separately

The following costs are funded directly by HTRS and must not be included in the grant budget:

Visiting Professor travel
Visiting Professor honorarium

Programme Objectives

The initiative aims to:

Improve hemophilia-focused medical education.
Strengthen physician knowledge.
Promote shared decision-making (SDM).
Increase awareness of emerging hemophilia therapies.
Encourage multidisciplinary collaboration.
Support patient-centered care.
Improve long-term patient outcomes.
Foster collaboration between healthcare professionals and patient advocacy groups.

Priority Areas

Applications should address one or more of the following educational priorities.

Hemophilia Care

Projects should improve clinical understanding of:

Diagnosis
Management
Long-term treatment
Comprehensive care

Shared Decision-Making (SDM)

Educational activities should promote:

Patient engagement
Collaborative treatment planning
Communication between clinicians and patients
Individualized care decisions

Emerging Therapeutic Options

Topics may include:

New treatment approaches
Advances in hemophilia therapy
Novel clinical practices
Future treatment strategies

Multidisciplinary Care

Programmes should encourage collaboration among:

Physicians
Nurses
Pharmacists
Allied health professionals
Patient advocates
Care teams

Who is Eligible?

Eligible applicants include U.S.-based organizations such as:

Medical schools
Nursing schools
Allied health schools
Dental schools
Pharmacy schools
Universities
Academic healthcare institutions
Patient advocacy groups
Nonprofit professional organizations
Medical societies

Only organizations may apply.

Applicant Requirements

Applicants must:

Be located in the United States.
Designate a Project or Program Lead employed by or contracted with the organization.
Clearly define partner roles if multiple organizations are involved.
Provide accreditation documentation if continuing education (CE/CME) credit will be offered.

Target Audience

Educational activities should serve:

Academic clinicians
Physician-scientists
Multidisciplinary care teams
Patient advocacy organizations
Healthcare professionals involved in hemophilia care

Application Requirements

Applicants must include:

Educational Needs Assessment

Describe:

Current medical knowledge gaps
Educational challenges
Unmet learning needs
Questions related to shared decision-making
Needs regarding emerging therapeutic options

Programme Agenda

Provide a proposed agenda outlining:

Educational sessions
Faculty activities
Learning objectives
Programme schedule

Expected Outcomes

Applicants should define measurable outcomes, including:

Physician knowledge improvements
Clinical practice changes
Patient care improvements
Six-month outcome metrics

Budget

Submit a detailed budget covering only eligible local logistical costs.

Accreditation Documentation

Organizations offering continuing education credit must include proof of accreditation.

Why This Programme Matters

Hemophilia treatment continues to evolve rapidly with new therapies and patient-centered care approaches.

This programme helps:

Improve clinical education.
Increase physician confidence.
Promote evidence-based practice.
Strengthen multidisciplinary care.
Enhance shared decision-making.
Improve patient outcomes.
Support collaboration between healthcare providers and advocacy organizations.

How to Apply

Step 1: Confirm Organizational Eligibility

Ensure your organization meets all eligibility requirements.

Step 2: Identify Educational Needs

Assess current knowledge gaps related to:

Hemophilia management
Shared decision-making
Emerging therapies
Clinical challenges

Step 3: Develop the Educational Programme

Prepare:

Learning objectives
Programme agenda
Expected outcomes
Evaluation methods

Step 4: Prepare the Budget

Develop a budget covering only eligible logistical expenses.

Exclude:

Faculty travel
Honoraria for the Visiting Professor

Step 5: Submit Supporting Documentation

Include:

Organizational information
Accreditation documentation (if applicable)
Educational needs assessment
Outcome metrics
Budget

Step 6: Submit the Application

Complete and submit the application according to the programme requirements.

Tips for a Strong Application

Applicants should:

Clearly identify educational gaps.
Demonstrate organizational capacity.
Develop measurable learning objectives.
Include realistic six-month outcomes.
Focus on patient-centered care.
Emphasize multidisciplinary collaboration.
Align the programme with current advances in hemophilia treatment.

Common Mistakes to Avoid

Avoid:

Including Visiting Professor travel costs in the budget.
Providing vague educational objectives.
Omitting outcome measures.
Submitting incomplete accreditation documentation.
Failing to explain unmet educational needs.
Developing agendas that do not address programme priorities.
Submitting incomplete applications.

Frequently Asked Questions (FAQs)

1. What is the Hemophilia Visiting Professorship Grant?

It is an Independent Medical Education grant funded by Pfizer and administered in collaboration with HTRS to support hemophilia-focused educational programmes hosted by eligible U.S. organizations.

2. How much funding is available?

Each selected organization may receive up to USD 6,000 to support local programme logistics.

3. Who can apply?

Eligible applicants include U.S.-based medical schools, universities, healthcare institutions, nonprofit organizations, medical societies, and patient advocacy groups.

4. What expenses are covered by the grant?

Funding supports local logistical costs such as meeting space, audiovisual services, staffing, planning, and event management. Travel expenses and honoraria for Visiting Professors are funded separately by HTRS.

5. Who are the Visiting Professors?

The Visiting Professors are distinguished experts selected by HTRS, with expertise matched to the educational needs identified by the recipient organization.

6. What information must applicants provide?

Applications should include an educational needs assessment, programme agenda, expected outcomes with six-month evaluation metrics, budget, and accreditation documentation where applicable.

7. Why is this programme important?

The programme strengthens hemophilia education by improving physician knowledge, promoting shared decision-making, encouraging multidisciplinary collaboration, and supporting better patient care through high-quality, evidence-based medical education.

Conclusion

The Pfizer and HTRS Independent Medical Education Grant for Hemophilia Visiting Professorships provides U.S. healthcare organizations with an opportunity to strengthen clinical education in hemophilia through expert-led educational programmes. With grants of up to USD 6,000 supporting local event logistics and HTRS covering faculty travel and honoraria, the initiative enables organizations to address important educational gaps, promote shared decision-making, and improve multidisciplinary care. Eligible organizations are encouraged to develop impactful programmes that enhance physician knowledge and contribute to better outcomes for people living with hemophilia.